The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Modular Facilities in Pharmaceutical / Biotechnology Industry, 2017-2030

  • Lowest Price Guaranteed From USD 2,499

  • Published
    October 2017

  • Pages
    250

  • View Count
    1795

Example Insights

  1. During the course of our study, we identified close to 20 companies that offer modular facilities to pharmaceutical / biotechnology industry. Majority of these companies are located in North America and Europe. Examples of players based in these regions include (in alphabetical order) Biologics Modular, G-CON Manufacturing, GE Healthcare Life Sciences, Germfree Laboratories, IPM Technologies, Jacobs Engineering Group, KeyPlants, ModWave, NNE, Pharmadule Morimatsu and WH Partnership.
  2. In addition, there are a number of players that specialize in providing modular cleanrooms; during our research, we identified more than 160 such companies. Of these, there are several companies that solely focus on serving the pharmaceutical and biotechnology industries; examples include (in alphabetical order, no specific shortlisting criteria)American Cleanroom Systems, Asgard Cleanroom Solutions, AWS BIO PHARMA Technologies, CID Associates, Clean Air Flow, Clean Room Depot, Environmental Systems Corporation, Modulus Cleanrooms and Shanghai HJ Modular Cleanroom.
  3. Several pharmaceutical and biotechnology companies have adopted the modular concept for constructing new facilities or expanding existing infrastructure. Examples of some established companies include (in alphabetical order)AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Pfizer, Merck, Roche, Novartis and Sanofi. Additionally, small to mid-sized companies that have installed modular facilities include (in alphabetical order) 3P Biotherapeutics, JHL Biotech, Just Biotherapeutics, Stragen Pharma and Strike Bio. In fact, in May 2016, JHL Biotech inaugurated a 2,400 square meters new manufacturing facility, based on the modular KUBio™ platform of GE Healthcare Sciences, at its site in Wuhan, China. More recently, in March 2017, Just Biotherapeutics contracted G-CON Manufacturing for the construction of a cGMP biologics facility in the Hangzhou Economic and Technology Development Area (HEDA) in China. The facility is currently under construction and is anticipated to be completed and operational in early 2018.
  4. A number of strategic collaborations have been inked in this domain. We came across over 35 collaborations established during the period 2014-H12017. Majority (~80%) of these collaborations are facility construction agreements. Prominent pharmaceutical / biotechnology modular facility or cleanroom providers that have entered into multiple partnerships include G-CON Manufacturing, GE Healthcare Life Sciences, AES Technology, M+W Group, and Pharmadule Morimatsu.
  5. Companies manufacturing niche and emerging therapeutic classes, such as personalized therapies, along with the rising number of biosimilars, hold significant promise for modular facility manufacturers. The adoption of such facilities is also likely to increase in emerging regions, some of which have struggled to meet GMP standards. In addition, CMOs, adopting modular facilities to reduce initial capital investment and handle multiple products, are expected to create incremental business opportunities for modular facility manufacturers.
  6. The pharmaceutical / biotechnology modular facilities market is anticipated to grow at an annualized rate of 8.9% during the period 2017 - 2030. Modular facilities for biologics manufacturing are expected to dominate (with more than 80% share) the market. Further, 85% of the overall market share is accounted for by facilities being used for manufacturing purposes. This is followed by facilities for R&D applications (12% of the overall market). In terms of type of facility, the opportunity is likely to be driven by construction of new facilities (65%) followed by modular expansions projects that will likely account for the remaining 35% of the market’s share.

Overview

The business strategies and operational processes in the pharmaceutical industry have regularly evolved over time. Over the past few years, there has been an increased pressure on drug manufacturers to optimize drug development costs and speed up the drug development process. Specifically, with the rise of personalized therapies and orphan drugs, manufacturers are now expected to produce significantly low volumes of a wide range of drugs owing to the patient specific nature of such therapies. In addition, with the increasing number of biosimilars in the pipeline, companies are aiming to reduce the time to market in order to ensure faster patient access. In general, the current market scenario demands the existing operational modes to be altered in such a way that the focus shifts to faster processes, lower manufacturing costs and smaller batch sizes.

Modular facilities have demonstrated tremendous potential in several fields; specifically, the shorter time taken to establish such facilities has a significant impact on expediting various operational processes. Over the years, the interest in such facilities has also gradually risen amongst drug manufacturers within the pharmaceutical and biopharmaceutical industries. In fact, various companies have already transitioned from establishing conventional manufacturing facilities (focused on the large-scale production of a single product) to using small, flexible and modular facilities that can handle multiple products, simultaneously. It has been reported that the time required for the construction of modular facilities, starting from design to approval, could be reduced to half the time required for the construction of conventional facilities. This is primarily due to the fact that modular buildings (modules) are typically constructed offsite, transported to the site and then assembled into fully functional entities. As a consequence of the approach used, facility construction, site preparation and regulatory documentation can proceed in parallel. This is very different from the traditional approach where the aforementioned activities have to be performed sequentially.

 

Scope of the Report

The ‘Modular Facilities in the Pharmaceutical / Biotechnology Industry, 2017-2030 report provides an extensive studyon the current market landscape and future outlook of modular facility manufacturers that cater to the demands of pharmaceutical and biopharmaceutical companies. The study presents an in-depth analysis of a diverse set of companies that provide complete modular facilities and / or modular cleanrooms to drug researchers / developers. In addition to other elements, the report features:

  • A review of the competitive market landscape of modular facility / modular cleanroom manufacturers with information on their geographical location (North America, Europe, Asia Pacific and rest of the world), establishment year, size (small-sized, mid-sized or large-sized) and type of industries served (pharmaceutical, biotechnology or others). It also includes information on regulatory certifications and recent projects undertaken by these companies.
  • Elaborate profiles of established players that offer a wide range of modular manufacturing solutions to pharmaceutical and biotechnology industries; each profile includes a brief overview of the company, information on its financial status, comprehensive modular services portfolio, recent collaborations, information on capability / facility expansionsand an informed future outlook.
  • An analysis of the most active regions based on the locations of modular manufacturing solution providers; the report contains schematic representations of world maps that clearly indicate the modular facility / cleanroom manufacturing hubs.
  • A review of emerging trends, including the combination of single use technologies / continuous processing technologies with modular facilities, the shift to using smaller, multi-purpose and multi-product modular facilities.
  • A discussion on key points that should be considered to facilitate the shift from using conventional facilities to modular facilities. We have provided a case study on JHL Biotech’s KUBio biomanufacturing facility, which was constructed by GE Healthcare Life Sciences in China.
  • A detailed discussion on the various growth drivers, such as the development of personalized medicines, biosimilars, orphan drugs, and the anticipated increase in adoption of modular solutions in emerging markets and by pharmaceutical / biopharmaceutical CMOs.
  • A detailed analysis of the collaborations and agreements, covering facility construction agreements, service alliances and acquisitions, which have been established amongst various stakeholders in the past few years.

The study features a detailed analysis on the likely evolution of the pharmaceutical / biotechnology modular manufacturing market over the time period 2017 to 2030. We have provided insights on the expected growth of the market in different regions, including North America, Europe, Asia Pacific and rest of the world. In addition, we have segmented the likely evolution of the market on the basis of type of construction component(process equipment, base building, mechanical, electrical, process utilities, process piping and others), size of the facility (small-sized, mid-sized and large-sized), type of product (small molecules, biologics and others), purpose of facility (manufacturing facility, R&D facility and others) and type of facility (new facility and expansions). In order to account for the uncertainties associated with some of the parameters used and to add robustness to our model, we have presented three different forecast scenarios, depicting conservative, base and optimistic tracks of the market’s evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. The opinions and insights presented in the report were also influenced by discussions with senior stakeholders in the industry. The report presents detailed transcripts of discussions held with Maik Jornitz (CEO, G-CON Manufacturing), Pär Almhem (President, ModWave), Sulogna Roy (Sales Manager / Project Manager, Zeton) and Vernon Solomon (President, Environmental Systems Corporation).

Contents

Chapter 2  provides an executive summary of the insights captured in our research. The summary offers a high level view on the current state of the market and its likely evolution in the mid-long term.

Chapter 3  provides a general overview of the modular design concept with information on its historical evolution, types of modules and the modular construction process. It also provides details related to the construction of modular facilities for use in the pharmaceutical / biotechnology industry along with the advantages of these facilities, and information on modular cleanrooms, including their classification and prevalent cleanroom standards.

Chapter 4  includes a comprehensive overview of the landscape of companies that offer pharmaceutical / biotechnology modular facilities. It features an analysis of these service providers on the basis of their geographical location, establishment year, company size and the type of industry served. Additionally, it contains information on regulatory certifications and examples of recent projects undertaken by these companies.

Chapter 5  features a comprehensive overview of the landscape of companies that specialize in offering modular cleanrooms. It features an analysis of the modular cleanroom providers on the basis of their geographical location, type of industry served and the type of modular cleanrooms offered. The chapter also provides information on the components of modular cleanrooms provided by different companies and regulatory certifications of these firms.

Chapter 6  contains detailed profiles of some of the key players that are actively providing modular facilities to pharmaceutical and biotechnology companies. Each company profile includes a brief overview of the company, financial information ( if available ), details on service offerings, recent developments and an informed future outlook.

Chapter 7  features an elaborate discussion and analysis of the collaborations and partnerships that have been inked amongst players in this market over the last five years (2012 - August 2017). We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements in this domain. It also lists other recent developments, such as facility / capability expansions and certifications, which have taken place in this domain.

Chapter 8  provides insights on the recent trends in the pharmaceutical / biotechnology industry that are expected to influence the adoption of modular facilities. Some of these trends include the integration of single use / continuous processing technologies with modular facilities, emergence of smaller, multi-purpose, multi-product modular facilities, and collaborations that have been established to provide integrated and flexible modular solutions.

Chapter 9  features a detailed discussion on potential areas, such as rise of personalized medicines, biosimilars and orphan drugs, and increasing adoption of modular solutions in emerging regions and CMOs, which are likely to act as growth drivers in the pharmaceutical / biotechnology modular facilities market, during the coming years.

Chapter 10  presents details on some modular facilities built by various pharmaceutical / biotechnology companies across different geographies. It also includes a discussion on why modular facilities may be preferred over traditional facilities in the long term. Additionally, the chapter includes a case study on JHL Biotech’s recent installation of GE Healthcare Life Sciences’ KUBio modular biomanufacturing facility, at the former company’s site in Wuhan, China.

Chapter 11  presents a comprehensivemarket forecast analysis, highlighting the future potential of the pharmaceutical / biotechnology modular facilities market till the year 2030. We have segregated the opportunity on the basis of type of construction component, size of the facility, type of product, purpose of facility and type of facility. Our estimates are backed by robust analysis of data procured from both secondary and primary sources.

Chapter 12  summarizes the overall report. It presents a list of key takeaways and offers our independent opinion on the current scenario and evolutionary trends that are likely to determine the future of this market in the mid-long term.

Chapter 13  is a collection of transcripts of discussions that were held with key stakeholders in this market.We have presented the details of interviews held with Maik Jornitz (CEO, G-CON Manufacturing), Pär Almhem (President, ModWave), Sulogna Roy (Sales Manager / Project Manager, Zeton) and Vernon Solomon (President, Environmental Systems Corporation).

Chapter 14  is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 15  is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

Table of Contents

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Modular Facilities in Pharmaceutical / Biotechnology Industry
3.1. Chapter Overview
3.2. Historical Background
3.3. The Concept of Modularization
3.3.1. Types of Modules
3.3.2. Modular Construction Process
3.4. Modular Construction in the Pharmaceutical Industry
3.4.1. Advantages of Modular Construction in the Pharmaceutical Industry
3.4.2. Pharmaceutical Modular Cleanrooms
3.4.2.1. Cleanroom Classifications and Standards
3.4.2.2. Advantages of Modular Cleanrooms
3.4.3. Regulations and Standards Concerning Modular Cleanroom Construction
 
4. Market Landscape of Modular Facility Manufacturers in Pharmaceutical / Biotechnology Industry
4.1. Chapter Overview
4.2. Modular Facility Manufacturers: Overall Market Landscape
4.2.1 Modular Facility Manufacturers: Distribution by Geography
4.2.2. Modular Facility Manufacturers: Analysis by Year of Establishment
4.2.3. Modular Facility Manufacturers: Distribution by Company Size
4.2.4. Modular Facility Manufacturers: Distribution by Type of Industry Served
4.2.5. Modular Facility Manufacturers: Regulatory Approvals and Certifications
4.2.6. Modular Facility Manufacturers: Modular Projects Executed / Undertaken
 
5. Market Landscape of Modular Cleanroom Providers in Pharmaceutical / Biotechnology Industry
5.1. Chapter Overview
5.2. Modular Cleanroom Providers: Overall Market Landscape
5.2.1. Modular Cleanroom Providers: Distribution by Geography
5.2.2. Modular Cleanroom Providers: Distribution by Type of Industry Served
5.2.3. Modular Cleanroom Providers: Distribution by Type of Modular Cleanrooms Offered
5.2.4. Modular Cleanroom Providers: Type of Cleanroom Components Offered
5.2.5. Modular Cleanroom Providers: Regulatory Approvals and Certifications
5.3. Modular Cleanroom Component Providers
 
6. Pharmaceutical / Biotechnology Modular Facilities: Key Solution Providers
6.1. Chapter Overview
 
6.2. GE Healthcare Life Sciences
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Modular Facility Offerings
6.2.4. Recent Developments
6.2.5. Future Outlook
 
6.3. G-CON Manufacturing
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Modular Facility Offerings
6.3.4. Recent Developments
6.3.5. Future Outlook
 
6.4. Pharmadule Morimatsu
6.4.1. Company Overview
6.4.2. Modular Facility Offerings
6.4.3. Recent Developments
6.4.4. Future Outlook
 
6.5. ModWave and KeyPlants
6.5.1. Company Overview
6.5.2. Modular Facility Offerings
6.5.3. Recent Developments
6.5.4. Future Outlook
 
6.6. Jacobs Engineering Group
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Modular Facility Offerings
6.6.4. Recent Developments
6.6.5. Future Outlook
 
6.7. NNE
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Modular Facility Offerings
6.7.4. Recent Developments
6.7.5. Future Outlook
 
6.8. IPM Technologies
6.8.1. Company Overview
6.8.2. Modular Facility Offerings
6.8.3. Recent Developments
6.8.4. Future Outlook
 
6.9. Germfree Laboratories
6.9.1. Company Overview
6.9.2. Modular Facility Offerings
6.9.3. Future Outlook
 
6.10. Biologics Modular
6.10.1. Company Overview
6.10.2. Modular Facility Offerings
6.10.3. Recent Developments

6.10.4. Future Outlook
 
6.11. WH Partnership
6.11.1. Company Overview
6.11.2. Modular Facility Offerings
6.11.3. Recent Developments
6.11.4. Future Outlook
 
7. Partnerships and Other Recent Developments
7.1. Chapter Overview
7.2. Partnership Models
7.3. Modular Facilities: List of Partnerships
7.3.1. Modular Facilities: Distribution of Partnerships by Year
7.3.2. Modular Facilities: Distribution of Partnerships by Type
7.3.3. Modular Facilities: Distribution of Partnerships by Geography
7.3.4. Modular Facilities: Leading Players by Number of Partnerships
7.4. Other Recent Developments
 
8. Recent Trends in Modular Facility Solutions
8.1. Chapter Overview
8.2. The Pharmaceutical Industry is Rapidly Adopting the Use of Smaller, Modular Facilities
8.3. The Integration of Single Use Technologies with Modular Facilities Offers Flexibility as well as Economic Benefits
8.4. Continuous Processing Technologies Offer Added Advantages to the Modular Approach
8.5. The Market is Abuzz with Partnership Activity as Service Providers are Entering into Strategic Alliances in Order to Expand their Service Portfolios
 
9. Future Growth Opportunities
9.1. Chapter Overview
9.2. Small Scale Facilities for Personalized Therapies are Likely to Emerge as a Key Growth Driver in the Long Term
9.3. In Order to Accelerate Time to Market and Stay Competitive, Several Biosimilar Manufacturers are Expected to Install Modular Facilities
9.4. Addressing the Niche Requirements, Orphan Indications Offer Additional Opportunities for Modular Facility Manufacturers
9.5. Emerging Regions are Likely to be Attractive Markets for Players in the Long Term
9.6. Expansions of Existing Facilities Using Modular Solutions are Projected to Increase Significantly
9.7. Several Contract Manufacturing Organizations are Gradually Shifting Towards Using Modular Solutions
 
10. Feasibility Study for Modular Facilities in Pharmaceutical / Biotechnology Industry
10.1. Chapter Overview
10.2. Modular Facility Projects Undertaken in the Pharmaceutical / Biotechnology Industry
10.3. Key Advantages of Modular Facilities
10.3.1. Rapid Construction Timelines of such Facilities Result in a Low-risk Investment
10.3.2. Despite the High Initial Investment, Modular Facilities Guarantee High Returns
 
10.4. Case Study: Modular Facility Based on KUBio Platform
10.4.1. GE Healthcare’s KUBio Platform: Overview
10.4.2. JHL Biotech’s KUBio Modular Project in China: Overview and Construction Details
 
11. Opportunity Analysis for the Global Pharmaceutical / Biotechnology Modular Solutions Market
11.1. Chapter Overview
11.2. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Historical Data, 2014-August 2017
11.2.1. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Number of Facilities Per Year, 2014-August 2017
11.2.2. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Type of Facility, 2014-August 2017
11.2.3. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Geography, 2014-August 2017
11.2.4. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Purpose of Facility, 2014-August 2017
11.2.5. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Investment, 2014-August 2017
11.2.6. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies):� Distribution by Size of the Facility, 2014-August 2017
 
11.3. Forecast Methodology
11.4. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030
11.4.1. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Construction Component
11.4.2. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Size of the Facility
11.4.3. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography
11.4.4. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Product Manufactured
11.4.5. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Facility
11.4.6. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Purpose of Facility
 
12. Conclusion
12.1. The Pharmaceutical / Biotechnology Industry is Witnessing an Increasing Need for Flexible, Modular Facilities
12.2. The Landscape of Companies Offering a Wide Range of Modular Solutions Has Evolved Considerably Over the Last Decade
12.3. Several Modular Cleanroom Providers are also Playing a Pivotal Role in the Market’s Evolution
12.4. Owing to the Benefits Offered by Modular Facilities, Their Adoption has Gradually Risen
12.5. The Growing Interest in Modular Facilities has Recently Led to the Establishment of Several Key Collaborations
12.6. The Integration of Emerging Technologies with Modular Solutions has Redefined the Applicability and Preferences for Modular Facilities
12.7. Overall, the Market is Anticipated to Witness Significant Growth in the Coming Decade
12.8. Concluding Remarks
 
13. Interview Transcripts
13.1. Chapter Overview
13.2. Maik Jornitz, CEO, G-CON Manufacturing
13.3. Par Almhem, President, ModWave
13.4. Sulogna Roy, Sales Manager / Project Manager, Zeton
13.5. Vernon Solomon, President, Environmental Systems Corporation
 
14. Appendix 1: Tabulated Data
 
15. Appendix 2: List of Companies and Organizations

List of Figures

Figure 3.1  Modular Construction: Applications
Figure 3.2  Modular Construction: Processes Involved
Figure 3.3  Modular and Conventional Buildings: Construction Timelines
Figure 3.4  Modular Construction: Advantages
Figure 4.1  Modular Facility Manufacturers: Distribution by Geography
Figure 4.2 Modular Facility Manufacturers: Cumulative Number of Companies by Year of Establishment
Figure 4.3  Modular Facility Manufacturers: Distribution by Company Size
Figure 4.4  Modular Facility Manufacturers: Distribution by Type of Industry Served
Figure 5.1  Modular Cleanroom Providers: Distribution by Geography
Figure 5.2  Modular Cleanroom Providers: Distribution by Type of Industry Served
Figure 5.3  Modular Cleanroom Providers: Distribution by Type of Cleanrooms Provided
Figure 6.1  GE Healthcare Life Sciences: Key Operations
Figure 6.2  GE Healthcare: Revenues, 2012-2016 (USD Billion)
Figure 6.3  GE Healthcare: Revenues by Business Divisions, 2016 (USD Billion)
Figure 6.4  G-CON Manufacturing: Types of PODs Offered
Figure 6.5  G-CON Manufacturing: Features of the Standard PODs
Figure 6.6  G-CON Manufacturing: Applications of PODs
Figure 6.7  Pharmadule Morimatsu: Modular Facility Fabrication Process
Figure 6.8  KeyPlants: Advantages of Modular Facility
Figure 6.9  Jacobs Engineering Group: Revenues, 2012-Q3 2017 (USD Billion)
Figure 6.10  Jacobs Engineering Group: Revenues by Services Offered, 2016 (USD Billion)
Figure 6.11  Jacobs Engineering Group: Revenues by Business Divisions, 2016 (USD Billion)
Figure 6.12 NNE: Services Portfolio
Figure 6.13 NNE: Annual Revenues, 2012-2016 (DKK Million)
Figure 6.14  NNE: Advantages of Bio on Demand Facility
Figure 6.15  IPM Technologies: Applications of Modular Facilities
Figure 6.16  Germfree Laboratories: Types and Applications of Modular Facilities Offered
Figure 6.17  Germfree Laboratories: Types of BioPharma Lab Modules
Figure 7.1  Modular Facilities: Cumulative Number of Partnerships by Year (2012-2017)
Figure 7.2  Modular Facilities: Distribution by Type of Partnerships
Figure 7.3  Modular Facilities: Distribution of Partnerships by Geography
Figure 7.4  Modular Facilities: Leading Players by Number of Partnerships
Figure 9.1  Modular Facilities Market: Future Growth Opportunities
Figure 10.1  Modular Facilities: Distribution by Company and Location
Figure 10.2  Modular Facilities: Example Manufacturers Along with their Clients
Figure 10.3  Traditional and Modular Facilities: Analysis of Risk and Probability of Success Across Different Phases of Product Development
Figure 10.4  Conventional and Modular Facilities: Comparison of Construction Timelines
Figure 10.5  JHL Biotech’s KUBio Manufacturing Facility: Construction Process
Figure 10.6  KUBio Facility: Construction Timeline
Figure 11.1  Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Number of Facilities Per Year, 2014-August 2017
Figure 11.2  Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Type of Facility, 2014-August 2017
Figure 11.3  Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Geography, 2014-August 2017
Figure 11.4  Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Type of Facility, 2014-August 2017
Figure 11.5  Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Investment (USD Million), 2014-August 2017
Figure 11.6  Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Size of the Facility (sq ft), 2014- August 2017
Figure 11.7  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Base Scenario (USD Billion)
Figure 11.8  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Construction Component, Base Scenario (USD Billion)
Figure 11.9  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Size of the Facility, Base Scenario (USD Billion)
Figure 11.10  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017, 2025 and 2030: Distribution by Geography (%)
Figure 11.11  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography, Base Scenario (USD Billion)
Figure 11.12  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Product Manufactured, Base Scenario (USD Billion)
Figure 11.13  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Facility, Base Scenario (USD Billion)
Figure 11.14  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Purpose of Facility, Base Scenario (USD Billion)
Figure 12.1  Global Pharmaceutical / Biotechnology Modular Facilities Market: 2017, 2025 and 2030 (USD Billion)

List of Tables

Table 3.1  Cleanrooms Classification Standards
Table 3.2  ISO and FED STD 209E: Cleanroom Classification
Table 4.1 Modular Facility Manufacturers
Table 4.2 Modular Facility Manufacturers: Distribution by Type of Industry Served
Table 4.3  Modular Facility Manufacturers: Regulatory Approvals and Certifications 
Table 4.4  Modular Facility Manufacturers: Modular Projects Executed / Undertaken
Table 5.1  Modular Cleanroom Providers
Table 5.2  Modular Cleanroom Providers: Distribution by Type of Industry Served
Table 5.3  Modular Cleanroom Providers: Distribution by Type of Modular Cleanrooms Offered
Table 5.4  Modular Cleanroom Providers: Distribution by Type of Cleanroom Components Offered
Table 5.5  Modular Cleanroom Providers: Regulatory Approvals and Certifications 
Table 5.6  Modular Cleanroom Component Providers
Table 6.1 Modular Manufacturing Facility Providers: List of Companies Profiled
Table 6.2  GE Healthcare Life Sciences: KUBio Facility Configurations
Table 6.3  G-CON Manufacturing: Dimensions of Standard PODs
Table 6.4  Pharmadule Morimatsu: Modular Projects Undertaken
Table 6.5  KeyPlants: Modular Projects Undertaken
Table 6.6  Jacobs Engineering Group: Pharma Modular Projects Undertaken
Table 6.7  NNE: Key Details of API Drug Substance Facility
Table 6.8  NNE: Key Details of Final Drug Product Facility
Table 6.9  IPM Technologies: Production Capacities of Modular Facilities
Table 6.10  Germfree Laboratories: Advantages of BioPharma Modules
Table 6.11  Germfree Laboratories: Advantages of BioPharma Lab Modules
Table 6.12  Biologics Modular: Features of Modular Cleanrooms
Table 6.13 Biologics Modular: Features of Modular Analytical Laboratories and Biorepositories
Table 7.1  Modular Facility Manufacturers: Partnerships
Table 7.2  Modular Facilities: List of Expansions and Certifications
Table 10.1  Modular Facilities: Distribution by Company and Location 
Table 10.2  PODs, Modular and Conventional Facilities: Comparison of Construction Investment and Financial Returns
Table 11.1  Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Historical Data, 2014-August 2017
Table 14.1  Modular Facility Manufacturers: Cumulative Number of Companies by Establishment Year
Table 14.2  Modular Facility Manufacturers: Distribution by Company Size
Table 14.3  Modular Facility Manufacturers: Distribution by Type of Industry Served
Table 14.4  Modular Cleanroom Providers: Distribution by Type of Industry Served
Table 14.5  Modular Cleanroom Providers: Distribution by Type of Cleanrooms Offered
Table 14.6  GE Healthcare: Revenues, 2012-2016 (USD Billion)
Table 14.7  GE Healthcare: Revenues by Business Divisions, 2016 (USD Billion)
Table 14.8  Jacobs Engineering Group: Revenues, 2012-Q3 2017 (USD Billion)
Table 14.9  Jacobs Engineering Group: Revenues by Services Offered, 2016 (USD Billion)
Table 14.10  Jacobs Engineering Group: Revenues by Business Divisions, 2016 (USD Billion)
Table 14.11  NNE: Annual Revenues, 2012-2016 (DKK Million)
Table 14.12  Modular Facilities: Cumulative Number of Partnerships by Year (2012-2017)
Table 14.13  Modular Facilities: Distribution by Type of Partnerships
Table 14.14  Modular Facilities: Distribution of Partnerships by Geography
Table 14.15  Modular Facilities: Leading Players by Number of Partnerships
Table 14.16  Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Number of Facilities Per Year, 2014-August 2017
Table 14.17  Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Type of Facility, 2014-August 2017
Table 14.18  Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Geography, 2014-August 2017
Table 14.19  Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Purpose of Facility, 2014-August 2017
Table 14.20  Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Investment, 2014-August 2017 (USD Million)
Table 14.21  Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies):  Distribution by Size of the Facility, 2014-August 2017
Table 14.22  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Conservative Scenario (USD Billion)
Table 14.23  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Base Scenario (USD Billion)
Table 14.24  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Optimistic Scenario (USD Billion)
Table 14.25  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Construction Component, Conservative Scenario (USD Billion)
Table 14.26  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Construction Component, Base Scenario (USD Billion)
Table 14.27  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Construction Component, Optimistic Scenario (USD Billion)
Table 14.28  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Size of the Facility, Conservative Scenario (USD Billion)
Table 14.29  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Size of the Facility, Base Scenario (USD Billion)
Table 14.30  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Size of the Facility, Optimistic Scenario (USD Billion)
Table 14.31  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography (%)
Table 14.32  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography, Conservative Scenario (USD Billion)
Table 14.33  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography, Base Scenario (USD Billion)
Table 14.34  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography, Optimistic Scenario (USD Billion)
Table 14.35 Global  Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Product Manufactured, Conservative Scenario (USD Billion)
Table 14.36  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Product Manufactured, Base Scenario (USD Billion)
Table 14.37  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Product Manufactured, Optimistic Scenario (USD Billion)
Table 14.38  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Facility, Conservative Scenario (USD Billion)
Table 14.39  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Facility, Base Scenario (USD Billion)
Table 14.40  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Facility, Optimistic Scenario (USD Billion)
Table 14.41  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Purpose of Facility, Conservative Scenario (USD Billion)
Table 14.42  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Purpose of Facility, Base Scenario (USD Billion)
Table 14.43  Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Purpose of Facility, Optimistic Scenario (USD Billion)
Table 14.44  Global Pharmaceutical / Biotechnology Modular Facilities Market: 2017, 2025 and 2030 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 209 Technologies
  2. A&M Project Services
  3. AASTHA CLEANROOM SYSTEMS
  4. ABN Cleanroom Technology
  5. Abtech
  6. ACH Engineering
  7. Acumen Technology
  8. A.D. Cleanrooms Engineering
  9. ADDvise
  10. AES Clean Technology
  11. Air Innovations
  12. Airgas
  13. Airology
  14. Air Micron Cleantech
  15. Aircare Projects 
  16. Airtech Systems
  17. AJNI Industries
  18. Ajinomoto North America
  19. AKERTEC
  20. Albian Group 
  21. Alembic Pharmaceuticals
  22. Allied Cleanrooms
  23. Alnylam Pharmaceuticals
  24. AME For Industry
  25. AM Cleanroom Build and Performance
  26. American Cleanroom Systems
  27. Angstrom Technology
  28. Aqvida
  29. Arthrex
  30. Asgard Cleanroom Solutions
  31. AstraZeneca
  32. AWS BIO PHARMA TECHNOLOGIES 
  33. Axenic Systems
  34. Bangalore Air Tech Solution
  35. Bassaire
  36. Baxter
  37. bc-technology
  38. Belcher Equipment
  39. Bode Equipment
  40. BioCon Solutions 
  41. Biogen
  42. Bigneat
  43. Bioinspection
  44. Biologics Modular
  45. Biosoft
  46. Bouygues Energies & Services
  47. Bristol-Myers Squibb
  48. Broad Sustainable Building
  49. Butler Manufacturing
  50. Cambridge Cleanroom
  51. CID Associates 
  52. Cipharm
  53. Clean Air Flow
  54. Clean Air Products
  55. Clean Air Systems
  56. Clean Air Technology
  57. Clean Modules
  58. Cleanrooms Australia
  59. Cleanroom Equipment
  60. Cleanroom Solutions
  61. ClearSphere
  62. Clean Room Depot 
  63. Clean Rooms International
  64. Clean Rooms Plus
  65. Clean Rooms West
  66. Clean Zone Technology 
  67. CleanAir Solutions
  68. Cleanroom Ceiling Systems (a division of Varni Enterprises)
  69. Cleanroom Results
  70. Cleanroom Synergy 
  71. Cleanrooms By United
  72. CleanZones
  73. CLEEMS
  74. Clestra Cleanroom
  75. Cook Imaging
  76. Connect 2 Cleanrooms
  77. CONSAB International
  78. CRB Consulting Engineers
  79. Design Filtration Microzone
  80. Dortek Hygienic Doors
  81. Dr. Reddy’s Laboratories
  82. Dynamic Manufacturing Solutions
  83. Ebtech Industrial Modular Building Solutions 
  84. Eli Lilly
  85. E- Pack Polymers
  86. Enbloc
  87. Environmental Systems Corporation
  88. Envair Electrodyne
  89. Fabtech Technologies International
  90. Filtration Technology 
  91. Firmament Technology
  92. Florida Cleanroom Systems
  93. Foothills Systems
  94. Flowstar 
  95. Fluor
  96. Galderma
  97. Guardtech Cleanrooms
  98. G-CON Manufacturing
  99. GE Healthcare Life Sciences
  100. Genentech
  101. Gerbig Engineering Company
  102. Germfree Laboratories
  103. Gilcrest Manufacturing
  104. GlaxoSmithKline
  105. Glowmax Engineers
  106. GMP Technical Solutions
  107. GMPMax Pharma
  108. Green Carrier Consultancy and Tech Solutions
  109. Halco Products
  110. Hectra Enviro Systems
  111. Hemair Systems 
  112. HEMCO Corporation
  113. HEPAire Products Corporation
  114. Hermetel Oy
  115. Hodess Construction
  116. Huntair
  117. Iberconcept
  118. Innclose
  119. Innotech Products
  120. Innovative Cleanroom Technologies
  121. InPlant Offices
  122. Instaspace
  123. Integrated Clean Room Technologies
  124. IPM Technologies
  125. Isoflex Systems
  126. IsoTech Design
  127. Jacobs Engineering Group 
  128. JHL Biotech
  129. JMC Project Services
  130. Just Biotherapeutics
  131. KABTech Corporation
  132. KeyPlants
  133. Kingspan
  134. Kleantech Engineering Systems
  135. KTEC Cleanroom Systems
  136. Labard Instruchem
  137. Labover
  138. Labworks International
  139. Lasco Services
  140. Lennox Clean Room Technologies
  141. Liberty Industries
  142. LifeTek Solutions
  143. LM Air Technology
  144. Longden Company
  145. Lonza
  146. Mabion
  147. Mach-Aire
  148. MAK Clean Air Systems
  149. Mallinckrodt Pharmaceuticals
  150. Mars Sterile Solutions
  151. McDonald's
  152. MDI
  153. MECART
  154. Medipharma
  155. Merck
  156. Merit Holdings
  157. Microbinc
  158. Microzone Corporation
  159. MK Precision
  160. Moduclean
  161. Mobius Controlled Environments
  162. Modubuild
  163. Modulus Cleanrooms
  164. Modular Cleanrooms
  165. ModWave
  166. Monmouth Scientific
  167. Morimatsu Industry Group
  168. M P Prime Structures
  169. MRC Systems
  170. MTX Contracts
  171. M+W Group
  172. Nano Clean
  173. National Partitions
  174. NextCell Pharma
  175. NGS Cleanroom Solutions
  176. Nicomac
  177. NNE
  178. Norwood Group
  179. Novartis
  180. Novo Nordisk
  181. Octapharma
  182. OCTANORM 
  183. OSB Prefab Technologies
  184. Pacific Environmental Technologies
  185. Panel Built
  186. Parteco
  187. PC Company
  188. Pfizer
  189. PermaTherm
  190. Pharmacia
  191. Pharmacon
  192. Pharmadule Morimatsu
  193. Pharmintech Turnkey Solutions
  194. Plascore
  195. Poppleton
  196. PortaFab
  197. Porta-King Building Systems
  198. Power And Motion
  199. Precision Air Technology
  200. Precision Cleanrooms
  201. Precision Engineering design
  202. ProCleanroom
  203. Progenitor Cell Therapy  
  204. QleanAir Scandinavia
  205. Riddhi Metals
  206. Rinac India
  207. Robert Soper
  208. Sartorius Stedim Biotech
  209. Sapphire Cleanrooms
  210. Sears Roebuck and Company
  211. SCHILLING ENGINEERING
  212. Schering-Plough
  213. Shanghai HJ Modular Cleanroom
  214. SRS Shelving + Rack Systems
  215. Skylark Engineering Technologies
  216. Simplex Isolation Systems
  217. SML Clean Room Solutions
  218. Solutions and Handling
  219. Span Construction and Engineering
  220. Srprefabs Modular Cleanroom
  221. Starrco
  222. Stefatos
  223. Sterlitech
  224. Stevenage BioScience Catalyst
  225. Stodec Products
  226. SUNBEL
  227. Suntec Teknopak
  228. Stragen Pharma
  229. Swedish Modules
  230. Synergy Thrislington
  231. SZ Airkey Environmental Tech & Eng
  232. Tabuk Pharmaceuticals
  233. TCM (The Cleanroom Market)
  234. Technical Air Products
  235. Ted Thorsen Material Handling
  236. Telstar Life Science Solutions
  237. Termovent
  238. Terra Universal
  239. Teruisi Pharmaceutical
  240. Teva Pharmaceutical
  241. The Softwall Shop 
  242. Travis Clean Air
  243. Tudela International
  244. Turnkey Modular Systems
  245. Ultrapure Technology
  246. United BioPharma
  247. United Partition Systems
  248. United Pharmaceuticals
  249. University of Tennessee Health Science Center
  250. Vanguard Modular Building Systems
  251. Vernick & Associates
  252. VRP CLEAN ROOM SYSTEMS
  253. Weaver Technologies
  254. Westbury Cleanrooms
  255. Western Environmental Corporation
  256. Whitenair Technologies
  257. WH Partnership
  258. w.w. Cannon
  259. XBiotech
  260. XCounter
  261. Xytel
  262. YRS Enterprises
  263. Zeton
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com